Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michelle L. Vassar"'
Autor:
Jeffry D. Shearer, Joshua J. Reece, Laurence Lemiale, Vladimir Savransky, Roy E. Barnewall, Boris Ionin, Mario H. Skiadopoulos, Michelle L. Vassar, Mark R. Perry, Sukjoon Park
Publikováno v:
Vaccine
A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125ed03c4c1cfb0b86dc9e04006f1af4
https://europepmc.org/articles/PMC8905666/
https://europepmc.org/articles/PMC8905666/
Autor:
Carrie A. Howland, Michelle L. Vassar, Randy L. Jones, Richard M. Chou, Roy E. Barnewall, Michael S. Anderson, Carol G. Riffle, David J. Guistino
Publikováno v:
Journal of biochemical and molecular toxicology. 31(12)
Ricin toxin may be used as a biological warfare agent and no medical countermeasures are currently available. Here, a well-characterized lot of ricin was aerosolized to determine the delivered dose for future pre-clinical efficacy studies. Mouse intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::324e21863bf4bee01b2090ac461e0bf2
https://pubmed.ncbi.nlm.nih.gov/28881502
https://pubmed.ncbi.nlm.nih.gov/28881502
Autor:
Ian Henderson, Nancy A. Niemuth, Karen Metcalfe, William Swiderski, Michelle L. Vassar, Jeffry D. Shearer
Publikováno v:
Vaccine. 28:7313-7318
The basis for efficacy of the recombinant botulinum vaccine, serotypes A and B (rBV A/B) is that neutralizing antibodies induced by vaccination bind to botulinum neurotoxin complex serotype A, subtype A1 (BoNT/A1) and serotype B, subtype B1 (BoNT/B1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654843062b7e2b631c1410abbb499b3e
https://doi.org/10.1016/j.vaccine.2010.08.076
https://doi.org/10.1016/j.vaccine.2010.08.076
Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1
Autor:
Karen Metcalfe, Michelle L. Vassar, Daniel C. Sanford, Jeffry D. Shearer, Ian Henderson, Roy E. Barnewall, Nancy A. Niemuth, Robert V. House
Publikováno v:
Clinical and vaccine immunology : CVI. 17(9)
A recombinant botulinum vaccine (rBV A/B) is being developed for protection against inhalational intoxication with botulinum neurotoxin (BoNT) complex serotype A, subtype A1 (BoNT/A1), and BoNT serotype B, subtype B1 (BoNT/B1). A critical component f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e04484d608d30776c7ffa044a602014
https://pubmed.ncbi.nlm.nih.gov/20660138
https://pubmed.ncbi.nlm.nih.gov/20660138